Which has better valuation and earnings, RVMD or ERAS?

Revolution Medicines is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revolution Medicines N/A N/A -$1.13B -$8.82 N/A Erasca N/A N/A -$124.55M -$0.95 N/A

Is RVMD or ERAS more profitable?

Erasca's return on equity of -38.43% beat Revolution Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Revolution Medicines N/A -88.20% -57.85% Erasca N/A -38.43% -32.05%

Does the media prefer RVMD or ERAS?

In the previous week, Revolution Medicines had 4 more articles in the media than Erasca. MarketBeat recorded 13 mentions for Revolution Medicines and 9 mentions for Erasca. Revolution Medicines' average media sentiment score of 1.20 beat Erasca's score of 1.01 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Erasca 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ERAS or GMAB?

Genmab A/S has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.95 N/A Genmab A/S $4.13B 4.90 $963M $1.27 25.57

Is ERAS or GMAB more profitable?

Genmab A/S has a net margin of 19.08% compared to Erasca's net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -38.43% -32.05% Genmab A/S 19.08% 14.89% 7.73%

Does the media prefer ERAS or GMAB?

In the previous week, Erasca had 3 more articles in the media than Genmab A/S. MarketBeat recorded 9 mentions for Erasca and 6 mentions for Genmab A/S. Erasca's average media sentiment score of 1.01 beat Genmab A/S's score of 0.40 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer UTHR or ERAS?

In the previous week, United Therapeutics had 14 more articles in the media than Erasca. MarketBeat recorded 23 mentions for United Therapeutics and 9 mentions for Erasca. Erasca's average media sentiment score of 1.01 beat United Therapeutics' score of 0.88 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 13 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or ERAS?

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Erasca. MarketBeat recorded 15 mentions for Ascendis Pharma A/S and 9 mentions for Erasca. Erasca's average media sentiment score of 1.01 beat Ascendis Pharma A/S's score of 0.88 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BBIO or ERAS?

In the previous week, BridgeBio Pharma had 4 more articles in the media than Erasca. MarketBeat recorded 13 mentions for BridgeBio Pharma and 9 mentions for Erasca. Erasca's average media sentiment score of 1.01 beat BridgeBio Pharma's score of 0.36 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Erasca (ERAS) Competitors

$15.88 -0.15 (-0.94%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$16.10 +0.22 (+1.37%)

As of 09/11/2026 07:55 PM Eastern

Compare

ERAS vs. RVMD, GMAB, UTHR, ASND, and BBIO

Should you buy Erasca stock or one of its competitors? Erasca's main competitors and comparable companies include Revolution Medicines (RVMD), Genmab A/S (GMAB), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), and BridgeBio Pharma (BBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Erasca compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Erasca's return on equity of -38.43% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Erasca	N/A	-38.43%	-32.05%

Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Erasca has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

In the previous week, Revolution Medicines had 4 more articles in the media than Erasca. MarketBeat recorded 13 mentions for Revolution Medicines and 9 mentions for Erasca. Revolution Medicines' average media sentiment score of 1.20 beat Erasca's score of 1.01 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Erasca	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 14.2% of Erasca shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Revolution Medicines is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$8.82	N/A
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

Revolution Medicines currently has a consensus price target of $226.17, suggesting a potential upside of 10.99%. Erasca has a consensus price target of $22.09, suggesting a potential upside of 39.11%. Given Erasca's higher possible upside, analysts clearly believe Erasca is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Revolution Medicines and Erasca tied by winning 7 of the 14 factors compared between the two stocks.

How does Erasca compare to Genmab A/S?

Erasca (NASDAQ:ERAS) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Erasca currently has a consensus target price of $22.09, suggesting a potential upside of 39.11%. Genmab A/S has a consensus target price of $39.50, suggesting a potential upside of 21.65%. Given Erasca's higher probable upside, analysts clearly believe Erasca is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Erasca has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

67.8% of Erasca shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 14.2% of Erasca shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
Genmab A/S	$4.13B	4.90	$963M	$1.27	25.57

Genmab A/S has a net margin of 19.08% compared to Erasca's net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
Genmab A/S	19.08%	14.89%	7.73%

In the previous week, Erasca had 3 more articles in the media than Genmab A/S. MarketBeat recorded 9 mentions for Erasca and 6 mentions for Genmab A/S. Erasca's average media sentiment score of 1.01 beat Genmab A/S's score of 0.40 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Genmab A/S beats Erasca on 11 of the 16 factors compared between the two stocks.

How does Erasca compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 14.2% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

United Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Erasca has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

United Therapeutics presently has a consensus price target of $646.00, suggesting a potential upside of 29.95%. Erasca has a consensus price target of $22.09, suggesting a potential upside of 39.11%. Given Erasca's higher probable upside, analysts plainly believe Erasca is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

United Therapeutics has a net margin of 41.56% compared to Erasca's net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Erasca	N/A	-38.43%	-32.05%

In the previous week, United Therapeutics had 14 more articles in the media than Erasca. MarketBeat recorded 23 mentions for United Therapeutics and 9 mentions for Erasca. Erasca's average media sentiment score of 1.01 beat United Therapeutics' score of 0.88 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	13 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.70	$1.33B	$27.95	17.79
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

Summary

United Therapeutics beats Erasca on 11 of the 15 factors compared between the two stocks.

How does Erasca compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Ascendis Pharma A/S has a net margin of 70.99% compared to Erasca's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Erasca	N/A	-38.43%	-32.05%

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Erasca. MarketBeat recorded 15 mentions for Ascendis Pharma A/S and 9 mentions for Erasca. Erasca's average media sentiment score of 1.01 beat Ascendis Pharma A/S's score of 0.88 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca has lower revenue, but higher earnings than Ascendis Pharma A/S. Erasca is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.18	-$258M	$12.89	20.44
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

67.8% of Erasca shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 14.2% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ascendis Pharma A/S currently has a consensus target price of $310.00, suggesting a potential upside of 17.64%. Erasca has a consensus target price of $22.09, suggesting a potential upside of 39.11%. Given Erasca's higher possible upside, analysts plainly believe Erasca is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Ascendis Pharma A/S has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Erasca has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Erasca on 11 of the 16 factors compared between the two stocks.

How does Erasca compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

BridgeBio Pharma currently has a consensus price target of $102.61, indicating a potential upside of 41.65%. Erasca has a consensus price target of $22.09, indicating a potential upside of 39.11%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, BridgeBio Pharma had 4 more articles in the media than Erasca. MarketBeat recorded 13 mentions for BridgeBio Pharma and 9 mentions for Erasca. Erasca's average media sentiment score of 1.01 beat BridgeBio Pharma's score of 0.36 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Erasca	N/A	-38.43%	-32.05%

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Erasca has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Erasca has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$713.07M	19.86	-$724.93M	-$3.57	N/A
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

Summary

BridgeBio Pharma beats Erasca on 9 of the 15 factors compared between the two stocks.

Get Erasca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERAS vs. The Competition

Export

Metric	Erasca	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.55B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-16.72	14.25	275.24	25.29
Price / Sales	N/A	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	15.12	15.12	10.33	6.20
Net Income	-$124.55M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-1.91%	-4.34%	-3.32%	-2.35%
1 Month Performance	-14.53%	-0.02%	-0.41%	-2.77%
1 Year Performance	917.95%	40.64%	19.21%	7.63%

Erasca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERAS Erasca	2.4264 of 5 stars	$15.88 -0.9%	$22.09 +39.1%	+886.3%	$5.55B	N/A	N/A	103	Positive News Analyst Forecast
RVMD Revolution Medicines	2.9753 of 5 stars	$210.02 -0.4%	$200.74 -4.4%	+340.7%	$45.20B	$11.58M	N/A	250	Positive News Analyst Forecast Insider Trade
GMAB Genmab A/S	4.3603 of 5 stars	$33.60 -2.4%	$39.50 +17.6%	+13.5%	$21.46B	$3.72B	26.46	3,029
UTHR United Therapeutics	4.2986 of 5 stars	$487.61 -0.5%	$646.00 +32.5%	+22.8%	$21.03B	$3.18B	17.45	1,400	Insider Trade
ASND Ascendis Pharma A/S	4.3814 of 5 stars	$270.56 -0.2%	$310.05 +14.6%	+33.3%	$16.91B	$814.57M	20.99	1,189	Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERAS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Erasca (ERAS) Competitors

ERAS vs. RVMD, GMAB, UTHR, ASND, and BBIO

How does Erasca compare to Revolution Medicines?

Summary

How does Erasca compare to Genmab A/S?

Summary

How does Erasca compare to United Therapeutics?

Summary

How does Erasca compare to Ascendis Pharma A/S?

Summary

How does Erasca compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS vs. The Competition

Erasca Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Erasca (ERAS) Competitors

ERAS vs. RVMD, GMAB, UTHR, ASND, and BBIO

How does Erasca compare to Revolution Medicines?

Is RVMD or ERAS more profitable?

Which has more risk and volatility, RVMD or ERAS?

Does the media prefer RVMD or ERAS?

Do institutionals & insiders hold more shares of RVMD or ERAS?

Which has better valuation and earnings, RVMD or ERAS?

Do analysts prefer RVMD or ERAS?

Summary

How does Erasca compare to Genmab A/S?

Do analysts recommend ERAS or GMAB?

Which has more volatility & risk, ERAS or GMAB?

Do institutionals and insiders hold more shares of ERAS or GMAB?

Which has better earnings and valuation, ERAS or GMAB?

Is ERAS or GMAB more profitable?

Does the media prefer ERAS or GMAB?

Summary

How does Erasca compare to United Therapeutics?

Do insiders and institutionals hold more shares of UTHR or ERAS?

Which has more volatility and risk, UTHR or ERAS?

Do analysts recommend UTHR or ERAS?

Is UTHR or ERAS more profitable?

Does the media prefer UTHR or ERAS?

Which has higher valuation and earnings, UTHR or ERAS?

Summary

How does Erasca compare to Ascendis Pharma A/S?

Is ASND or ERAS more profitable?

Does the media prefer ASND or ERAS?

Which has stronger earnings & valuation, ASND or ERAS?

Do insiders & institutionals hold more shares of ASND or ERAS?

Do analysts recommend ASND or ERAS?

Which has more risk & volatility, ASND or ERAS?

Summary

How does Erasca compare to BridgeBio Pharma?

Do analysts prefer BBIO or ERAS?

Does the media favor BBIO or ERAS?

Is BBIO or ERAS more profitable?

Do institutionals and insiders hold more shares of BBIO or ERAS?

Which has more volatility and risk, BBIO or ERAS?

Which has better earnings & valuation, BBIO or ERAS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS vs. The Competition

Erasca Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools